State of Delaware - FY24 Budget
It is probable that the COVID-19 pandemic will have an impact on health care costs. In performing this analysis to develop health care cost estimates for GHIP, we have not explicitly reflected adjustments due to the impact of COVID-19. Due to the high degree of uncertainty associated with this pandemic, results may vary from the estimates provided.
August 2023 Willis Towers Watson

Proprietary and Confidential

State of Delaware

FY24 Budget August 2023

	Estimated FY 2024								
	as of August 2023 ¹								
Balance Forward ²									
Balance Forward	S	58,840,987							
Operating Revenues									
Premium Contributions									
Highmark	\$	783,334,287	65.10%						
Aetna	S	203,489,467	16.91%						
Total Premium Contributions	3	986,823,754							
Other Revenues									
Medicare Retiree Prescription Subsidy Program (EGWP) ³	S	938,720	0.08%						
Federal Reinsurance ³	\$	25,038,872	2.08%						
Prescription Drug Rebates - Commercial ⁴	\$	79,226,612	6.58%						
Prescription Drug Rebates - EGWP ⁴	\$	59,741,511	4.96%						
Prescription True Up/Yr End Recon Pymts ⁵	S	13,466,470	1.12%						
Medicare Part D - Coverage Gap Discount ³	S	30,765,967	2.56%						
Participating Group Fees ⁶	\$	7,315,468	0.61%						
Other Revenues	\$	-	0.00%						
Total Other Revenues	\$	216,493,618							
Total Operating Revenues	\$	1,203,317,372							
Operating Expenses									
Claims ⁷									
Highmark	S	616,427,996	49.33%						
Aetna	\$	183,904,233	14.72%						
CVS (non-Plan D)	S	206,681,209	16.54%						
CVS (Plan D)	\$	195,930,427	15.68%						
Total Claims	\$	1,202,943,865							
Other Expenses									
Program Fees and Costs (Vendor ASO Fees)	\$	39,812,591	3.19%						
Office Expenses	\$	3,719,461	0.30%						
Employee Assistance Data Warehouse	S	479,742	0.04%						
Consultant Fees	S	722,592 1,500,000	0.06%						
COBRA Fees	\$	90,820	0.12%						
ACA Fees	S	365,875	0.01%						
Total Other Expenses	\$	46,691,080							
Total Operating Expenses	\$	1,249,634,945							
Net Income	\$	(46,317,573)							
Fund Equity Balance	\$	12,523,414							
Claim Liability	s	71,700,000							
Minimum Reserve	s	28,600,000							
GHIP Surplus (After Reserves)	\$	(87,776,586)							
WTW Budget (\$M) ⁸	s	1,031.3							
Average Members		132,432	TYPA FO						

¹ Based on claims experience for the period 7/1/2022 - 6/30/2023; headcounts reflect July 2023 open enrollment with 1% growth during FY24; 5% medical (3% Medicfill) and 8% Rx trend; EGWP revenues and prescription drug rebates based on the period revenues will be paid

FT24 projected canna renex Cvs manes turnex contains improvements.

**WTW Budget erpresents the FY24 projected expenses based on assumptions approved by the SEBC, updated with claims and enrollment data through June 2023; WTW Budget equals total operating expenses, less ACA and consultant fees, less total other revenues

Note: It is evident that the COVID-19 pandernic will have an impact on health care costs. We have used available information and reasonable estimation techniques to develop health care cost stimates for the CHIP that reflect the impact of COVID-19. However due to the high degree of uncertainty associated with this pandemic, results may vary from the estimates provided.

² Balance Forward reflects actual balance as of June 2023 Fund Equity Report

³ EGWP revenue reflects actual revenues received through June 2023; remaining revenues through CY23 and CY24 based on projected PMPM payments provided by CVS

⁴ FY24 rebates based on when rebates will be received by GHIP; assumes 60 day lag on CVS rebate payments

 $^{^{5}}$ Reflects CY22 federal reinsurance true-up payment expected to be received in January 2024

⁶ Participating Group Fees shown for FY24 are estimated based on FY23 fees and assumed FY24 headcounts and premiums

⁷FY24 projected claims reflect CVS market check contract improvements

State of Delaware

FY24 Budget1

August 2023

Operating Revenues		July	August	S	eptember	October	No	ovember	December		January	F	ebruary	March		April		May	June		TOTAL
Premium Contributions	_			_						Ļ.		_			_						
Highmark	\$	62,475,578	\$ 65,266,165	\$	65,266,165	\$ 65,428,722	\$	65,428,722	\$ 65,428,722	\$	65,591,684		65,591,684		\$	65,755,052	\$	65,755,052	65,755,052	\$	783,334,287
Aetna Total Premium Contributions	\$	16,214,018 81,044,522	\$ 16,955,820 \$ 81.044.522	\$	16,955,820 81,044,522	\$ 16,998,051 \$ 82,426,774	\$	16,998,051 82,426,774	\$ 16,998,051 \$ 82,426,774	\$	17,040,388 82.632.073		17,040,388 82.632.073	\$ 17,040,388 \$ 82,632,073	\$	17,082,830 82,837,883	5	17,082,830 S	17,082,830 82,837,883	\$	203,489,467 986,823,754
Total Premium Contributions	3	81,044,522	\$ 81,044,522	•	81,044,522	\$ 82,426,774	3	82,426,774	\$ 82,426,774	Ъ	82,632,073	3	82,632,073	\$ 82,632,073	Þ	82,837,883	Þ	82,837,883	\$ 82,837,883	\$	986,823,754
Other Revenues																					
Medicare Retiree Prescription Subsidy Program (EGWP) ²	\$	4,835	\$ (95,393)) \$	(95,393)	\$ (143,446)) \$	(143,446)	\$ (143,446)	\$	258,846	\$	258,846	\$ 258,846	\$	259,490	\$	259,490	\$ 259,490	\$	938,720
Federal Reinsurance ²	\$	1,933,426	\$ 1,933,426	\$	1,933,426	\$ 1,938,241	\$	1,938,241	\$ 1,938,241	\$	2,234,529	\$	2,234,529	\$ 2,234,529	\$	2,240,095	\$	2,240,095	\$ 2,240,095	\$	25,038,872
Prescription Drug Rebates - Commercial ³	\$		\$ 18.905.075	\$		\$ -	\$	19.763.907	\$ -	\$		\$	20.049.085	S -	S		S	20.508.544		\$	79.226.612
Prescription Drug Rebates - EGWP ³	\$	-	\$ 15.013.124	\$	-	\$ -	\$	14.673.179	\$ -	\$	-	\$	14.797.388	s -	s	-	s	15,257,819	5 -	\$	59,741,511
Prescription True Up / Yr End Recon Pymts ⁴	\$	-	s -	\$	-	s -	\$	-	\$ -	\$	13,466,470	\$	-	\$ -	s	-	\$	- 1	5 -	\$	13,466,470
Medicare Part D - Coverage Gap Discount ²	\$		\$ -	\$	-	\$ 7.548.906	\$	-	\$ 9.213.030	\$		\$	-	\$ 9,446,543	s	-	s	- 9	4.557.489	\$	30,765,967
Participating Group Fees ⁵	\$	607.349	\$ 607.349	9	607.349	\$ 608.862	\$	608.862	\$ 608,862	¢	610.379	\$	610.379	\$ 610,379	Š	611.899	9	611.899	611.899	¢	7,315,468
Other Revenues	\$		\$ -	\$		\$ -	\$	- 000,002	\$ -	\$	010,573	\$	010,573	\$ -	s	011,033	s	- 9	\$ -	\$	7,515,400
Total Other Revenues	\$	2,545,610	\$ 36.363.582	\$	2.445.382	\$ 9,952,563	\$	36.840.744	\$ 11,616,687	\$	16.570,223	\$	37.950.226	\$ 12.550.297	Š	3.111.484	Š	38.877.847	7.668.973	\$	216.493.618
	Ť	_,_,_,_,	,,	Ť	_,,	* -,,,,,,	Ť	20,0 10,1 11		Ť		Ť	0.1,000,000	*	Ť	4,111,101		99,911,911	,,	*	=101.0010.0
Total Operating Revenues	\$	83,590,133	\$ 117,408,104	\$	83,489,904	\$ 92,379,337	\$ 1	119,267,518	\$ 94,043,461	\$	99,202,296	\$ 1	120,582,299	\$ 95,182,369	\$	85,949,366	\$	121,715,729	90,506,855	\$	1,203,317,372
										_					1						
Operating Expenses		July	August	S	<u>eptember</u>	<u>October</u>	No	<u>ovember</u>	<u>December</u>		<u>January</u>	E	<u>ebruary</u>	<u>March</u>		<u>April</u>		Mav	June		TOTAL
Claims ⁶	+			+			-			Н			-		-						
Highmark	6	45.648.034	\$ 57.060.042	•	45.648.034	\$ 54.152.501	s	43.322.001	\$ 43.322.001	¢	62,735,319	¢	50.188.255	\$ 50.188.255	۹.	63.139.828	•	50.511.862	50.511.862	2	616.427.996
Aetna	\$	13,618,568	\$ 13.618.568	\$	17.023.210	\$ 12.924.623		12.924.623	\$ 16.155.779	\$	14.973.091		14.973.091	\$ 18,716,364	Š	15.069.636	Š	18.837.045	15.069.636	\$	183,904,233
CVS (non-Plan D)	\$	16,081,504	\$ 16.081.504	\$	16,081,504	\$ 16,630,463	\$	16.630.463	\$ 16,630,463	\$	17.342.055		17.342.055	\$ 17,342,055	S	18.839.714	s	18,839,714	18.839.714	\$	206,681,209
CVS (Plan D)	\$	15,237,235	\$ 15,237,235	\$	15.237.235	\$ 15,664,731	\$	15,664,731	\$ 15,664,731	\$	16,465,931		16.465.931	\$ 16,465,931	Š	17.942.245	Š	17,942,245	17,942,245	\$	195,930,427
Total Claims	\$	90,585,342	\$ 101,997,350	\$	93,989,984	\$ 99,372,319	\$	88,541,818	\$ 91,772,974	\$	111,516,396	\$	98,969,332	\$ 102,712,605	\$	114,991,423	\$	106,130,866	102,363,457	\$	1,202,943,865
Other Expenses				-			-			-		-									
Program Fees and Costs (Vendor ASO Fees)	\$	3.307.357	\$ 3,307,357	•	3.307.357	\$ 3.314.252	\$	3.314.252	\$ 3.314.252	¢	3.321.163	\$	3.321.163	\$ 3.321.163	٠	3.328.092	•	3.328.092	3.328.092	\$	39.812.591
Office Expenses	\$	309.955	\$ 309,955			\$ 309,955		309.955			309,955		309.955	\$ 309,955		309,955	Š	309.955		\$	3,719,461
Employee Assistance	\$	39.979	\$ 39,979		39,979	\$ 39.979		39,979			39.979		39,979	\$ 39.979		39.979	s	39.979	39,979	\$	479.742
Data Warehouse	\$	60,216	\$ 60,216	S.	60,216	\$ 60,216	\$	60,216	\$ 60,216	\$	60,216	\$	60,216	\$ 60,216	S	60,216	S	60.216	60,216	\$	722,592
Consultant Fees	\$	125,000	\$ 125,000	\$	125,000	\$ 125,000	\$	125,000	\$ 125,000	\$	125,000	\$	125,000	\$ 125,000	\$	125,000	\$	125,000	125,000	\$	1,500,000
COBRA Fees	\$	7,568	\$ 7,568	\$	7,568	\$ 7,568	\$	7,568	\$ 7,568	\$	7,568	\$	7,568	\$ 7,568	\$	7,568	\$	7,568	7,568	\$	90,820
ACA Fees	\$	365,875	\$ -	\$	-	\$ -	\$	-	\$ -	\$	-	\$	-	\$ -	\$	-	\$	- 3	-	\$	365,875
Total Other Expenses	\$	4,215,950	\$ 3,850,075	\$	3,850,075	\$ 3,856,969	\$	3,856,969	\$ 3,856,969	\$	3,863,881	\$	3,863,881	\$ 3,863,881	\$	3,870,810	\$	3,870,810	3,870,810	\$	46,691,080
Total Operating Expenses	\$	94,801,292	\$ 105,847,425	\$	97,840,059	\$ 103,229,288	\$	92,398,788	\$ 95,629,943	\$	115,380,277	\$ 1	102,833,213	\$ 106,576,486	\$	118,862,233	\$	110,001,676	106,234,267	\$	1,249,634,945
Net Income	-	(\$11,211,159)	\$11,560,679	-	(\$14,350,154)	(\$10,849,951)) \$	26,868,730	(\$1,586,482)	-	(\$16,177,981)	١	\$17,749,086	(\$11,394,117)	((\$32,912,866)		\$11,714,053	(\$15,727,411)		(\$46,317,573)
Amount Carried Forward ⁷	\$	58,840,987	\$ 47,629,828	\$	59,190,507	\$ 44,840,353	\$	33,990,402	\$ 60,859,133	\$	59,272,650	\$	43,094,669	\$ 60,843,755	\$	49,449,638	\$	16,536,772	\$ 28,250,825	\$	58,840,987
Fund Equity Balance	\$	47,629,828	\$ 59,190,507	\$	44,840,353	\$ 33,990,402	\$	60,859,133	\$ 59,272,650	\$	43,094,669	\$	60,843,755	\$ 49,449,638	\$	16,536,772	\$	28,250,825	12,523,414	\$	12,523,414
	Ė	7,	, , ,	Ė	//		Ė	,,	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Ė	.,,,	Ė	,, .,	, .,		,,, .=		., .,,.	. , , , , , , , , , , , , , , , , , , ,		, ., .,
GHIP Surplus (After Reserves)		(\$52,670,172)	(\$41,109,493)) ((\$55,459,647)	(\$66,309,598)	(\$	39,440,867)	(\$41,027,350)		(\$57,205,331)	(\$	\$39,456,245)	(\$50,850,362)	1 ((\$83,763,228)		(\$72,049,175)	(\$87,776,586)		(\$87,776,586)

¹ Based on claims experience for the period 7/1/2022 - 6/30/2023; headcounts reflect July 2023 open enrollment with 1% growth during FY24; 5% medical (3% Medicfill) and 8% Rx trend; EGWP revenues and prescription drug rebates based on the period revenues will be paid

Bottom Cover the coverage for the GMIP that reflect the impact of COVID-19 pandemic will have an impact on health care costs. We have used available information and reasonable estimation techniques to develop health care cost estimates for the GHIP that reflect the impact of COVID-19. However due to the high degree of uncertainty associated with this pandemic, results may vary from the

² EGWP revenue reflects actual revenues received through June 2023; remaining revenues through CY23 and CY24 based on projected PMPM payments provided by CVS

³ FY24 rebates based on when rebates will be received by GHIP; assumes 60 day lag on CVS rebate payments

 $^{^{\}rm 4}$ Reflects CY22 federal reinsurance true-up payment expected to be received in January 2024

⁵ Participating Group Fees shown for FY24 are estimated based on FY24 fees and assumed FY23 headcounts and premiums

⁶ FY24 projected claims reflect CVS market check contract improvements

⁷ Balance Forward reflects actual balance as of June 2023 Fund Equity Report

Operating Revenues	<u>July</u>	<u>August</u>	<u>September</u>	October	<u>November</u>	December	<u>January</u>	<u>February</u>	<u>March</u>	<u>April</u>	<u>Mav</u>	June	TOTAL
Premium Contributions Highmark	\$ 62,475,578	\$ 127.741.744	\$ 193,007,909 \$	258.436.632	\$ 323.865.354	\$ 389,294,076	\$ 454.885.761	\$ 520,477,445	\$ 586.069.130	\$ 651.824.182	\$ 717.579.234	\$ 783.334.287 \$	783.334.287
Aetna	\$ 16.214.018	\$ 33,169,838	\$ 50.125.658 \$	67.123.709		\$ 101,119,812			\$ 152,240,976	\$ 169,323,806	\$ 186,406,637		203,489,467
Total Premium Contributions	\$ 81.044.522		\$ 243.133.567 \$	325.560.341		\$ 490,413,889	\$ 573.045.961			\$ 821,147,989			
Total Total Octobasion	U 01,011,022	ψ 102,000,040	ψ <u>2-10,100,001</u> ψ	020,000,011	407,007,110	400,110,000	ψ 070,040,001	Ψ 000,010,0001	0 700,010,100	Q 021,147,000	Ψ 000,000,011	000,020,701	000,020,104
Other Revenues													
Medicare Retiree Prescription Subsidy Program (EGWP) ²	\$ 4,835	\$ (90,558)	\$ (185,951) \$	(329,397)	\$ (472,843)	\$ (616,289)	\$ (357,443)	\$ (98,597)	\$ 160,249	\$ 419,739	\$ 679,229	\$ 938,720 \$	938,720
Federal Reinsurance ²	\$ 1,933,426	\$ 3,866,851	\$ 5,800,277 \$	7,738,518	\$ 9,676,760	\$ 11,615,001	\$ 13,849,530	\$ 16,084,059	\$ 18,318,588	\$ 20,558,683	\$ 22,798,777	\$ 25,038,872 \$	25,038,872
Prescription Drug Rebates - Commercial ³	\$ -	\$ 18,905,075	\$ 18,905,075 \$	18,905,075	\$ 38,668,983	\$ 38,668,983	\$ 38,668,983	\$ 58,718,068	\$ 58,718,068	\$ 58,718,068	\$ 79,226,612	\$ 79,226,612 \$	79,226,612
Prescription Drug Rebates - EGWP ³	\$ -	\$ 15,013,124	\$ 15,013,124 \$	15,013,124	\$ 29,686,304	\$ 29,686,304	\$ 29,686,304	\$ 44,483,692	\$ 44,483,692	\$ 44,483,692	\$ 59,741,511	\$ 59,741,511 \$	59,741,511
Prescription True Up / Yr End Recon Pymts ⁴	s -	S -	s - s	-	\$ -	S -	\$ 13.466.470	\$ 13,466,470	\$ 13,466,470	\$ 13,466,470	\$ 13,466,470	\$ 13,466,470 \$	13,466,470
Medicare Part D - Coverage Gap Discount ²	s -	S -	s - s	7.548.906	\$ 7.548.906	\$ 16.761.935	\$ 16.761.935	\$ 16,761,935	\$ 26,208,478	\$ 26,208,478	\$ 26,208,478	\$ 30,765,967 \$	30,765,967
Participating Group Fees ⁵	\$ 607.349	\$ 1,214,699	\$ 1,822,048 \$	2,430,911	\$ 3,039,773	\$ 3,648,635	\$ 4,259,014			\$ 6.091.670			7,315,468
Other Revenues	\$ -		\$ - \$	-,,		\$ -	\$ -		S -	\$ -	\$ -		.,,
Total Other Revenues	\$ 2,545,610	\$ 38,909,192	\$ 41,354,574 \$	51,307,138	\$ 88,147,882	\$ 99,764,569	\$ 116,334,792	\$ 154,285,018	\$ 166,835,315	\$ 169,946,799	\$ 208,824,646	\$ 216,493,618 \$	216,493,618
Total Operating Revenues	\$ 83,590,133	\$ 200,998,237	\$ 284,488,141 \$	376,867,478	\$ 496,134,997	\$ 590,178,458	\$ 689,380,753	\$ 809,963,052	\$ 905,145,421	\$ 991,094,788	\$ 1,112,810,517	\$ 1,203,317,372 \$	1,203,317,372
Operating Expenses	July	August	September	October	November	December	January	February	March	April	Mav	June	TOTAL
Operating Expenses	2011	Audust	<u>September</u>	<u>OCTOBEL</u>	HOVEINDEL	December	<u> zanuar v</u>	TEDIGALY	<u>Piarcii.</u>	AVIII	1-16 V	zune	TOTAL
Claims ⁶													
Highmark	\$ 45,648,034	\$ 102,708,076	\$ 148,356,110 \$	202,508,611	\$ 245,830,612	\$ 289,152,613	\$ 351,887,932	\$ 402,076,187	\$ 452,264,443	\$ 515,404,271	\$ 565,916,133	\$ 616,427,996 \$	616,427,996
Aetna	\$ 13,618,568	\$ 27,237,136	\$ 44,260,346 \$	57,184,969		\$ 86,265,371	\$ 101,238,462	\$ 116,211,553	\$ 134,927,917	\$ 149,997,552	\$ 168,834,597	\$ 183,904,233 \$	183,904,233
CVS (non-Plan D)	\$ 16,081,504		\$ 48,244,513 \$	64,874,977						\$ 169,001,782			
CVS (Plan D)	\$ 15,237,235		\$ 45,711,706 \$	61,376,437		\$ 92,705,900	\$ 109,171,830			\$ 160,045,936	\$ 177,988,182		195,930,427
Total Claims	\$ 90,585,342	\$ 192,582,692	\$ 286,572,676 \$	385,944,994	\$ 474,486,813	\$ 566,259,787	\$ 677,776,183	\$ 776,745,515	\$ 879,458,119	\$ 994,449,542	\$ 1,100,580,408	\$ 1,202,943,865 \$	1,202,943,865
Other Expenses													
Program Fees and Costs (Vendor ASO Fees)	\$ 3,307,357	\$ 6.614.714	\$ 9,922,071 \$	13.236.323	\$ 16,550,574	\$ 19.864.826	\$ 23,185,989	\$ 26,507,152	\$ 29.828.315	\$ 33.156.407	\$ 36,484,499	\$ 39,812,591 \$	39.812.591
Office Expenses	\$ 309.955		\$ 929,865 \$	1,239,820		\$ 1,859,730	\$ 2,169,685			\$ 3,099,551	\$ 3,409,506	\$ 3,719,461 \$	3,719,461
Employee Assistance	\$ 39,979	\$ 79,957	\$ 119,936 \$	159,914	\$ 199,893	\$ 239,871	\$ 279,850	\$ 319,828	\$ 359,807	\$ 399,785	\$ 439,764	\$ 479,742 \$	479,742
Data Warehouse	\$ 60,216	\$ 120,432	\$ 180,648 \$	240,864	\$ 301,080	\$ 361,296	\$ 421,512	\$ 481,728	\$ 541,944	\$ 602,160	\$ 662,376	\$ 722,592 \$	722,592
Consultant Fees	\$ 125,000	\$ 250,000	\$ 375,000 \$	500,000		\$ 750,000				\$ 1,250,000	\$ 1,375,000		1,500,000
COBRA Fees	\$ 7,568		\$ 22,705 \$	30,273						\$ 75,683	\$ 83,251		90,820
ACA Fees	\$ 365,875		\$ 365,875 \$	365,875		\$ 365,875			\$ 365,875	\$ 365,875	\$ 365,875		365,875
Total Other Expenses	\$ 4,215,950	\$ 8,066,025	\$ 11,916,100 \$	15,773,069	\$ 19,630,038	\$ 23,487,008	\$ 27,350,889	\$ 31,214,770	\$ 35,078,651	\$ 38,949,461	\$ 42,820,270	\$ 46,691,080 \$	46,691,080
Total Operating Expenses	\$ 94,801,292	\$ 200,648,717	\$ 298,488,775 \$	401,718,063	\$ 494,116,851	\$ 589,746,794	\$ 705,127,071	\$ 807.960.284	\$ 914,536,770	\$ 1.033.399.002	\$ 1,143,400,678	\$ 1,249,634,945 \$	1,249,634,945
Total Operating Expenses	\$ 34,001,232	\$ 200,040,717	\$ 230,400,113 \$	401,710,003	\$ 434,110,031	\$ 303,140,134	\$ 703,127,071	\$ 007,300,204	\$ 314,330,770	\$ 1,000,000,002	\$ 1,143,400,070	\$ 1,243,034,343 ¢	1,243,034,343
Net Income	\$ (11,211,159)	\$ 349,520	\$ (14,000,634) \$	(24,850,585)	\$ 2,018,146	\$ 431,663	\$ (15,746,318)	\$ 2,002,768	\$ (9,391,349)	\$ (42,304,215)	\$ (30,590,162)	\$ (46,317,573) \$	(46,317,573)
Amount Carried Forward ⁷	\$ 58.840.987	\$ 58.840.987	\$ 58.840.987 \$	58.840.987	\$ 58.840.987	\$ 58.840.987	\$ 58.840.987	\$ 58.840.987	\$ 58.840.987	\$ 58.840.987	\$ 58.840.987	\$ 58.840.987 \$	58.840.987
													.,,
Fund Equity Balance	\$ 47,629,828	\$ 59,190,507	\$ 44,840,353 \$	33,990,402	\$ 60,859,133	\$ 59,272,650	\$ 43,094,669	\$ 60,843,755	\$ 49,449,638	\$ 16,536,772	\$ 28,250,825	\$ 12,523,414 \$	12,523,414
GHIP Surplus (After Reserves)	(\$52,670,172)	(\$41,109,493)	(\$55,459,647)	(\$66,309,598)	(\$39,440,867)	(\$41,027,350)	(\$57,205,331)	(\$39.456.245)	(\$50.850.362)	(\$83,763,228)	(\$72,049,175)	(\$87,776,586)	(\$87,776,586)

¹ Based on claims experience for the period 7/1/2022 - 6/30/2023; headcounts reflect July 2023 open enrollment with 1% growth during FY24; 5% medical (3% Medicfill) and 8% Rx trend; EGWP revenues and prescription drug rebates based on the period revenues will be paid

Note: It is evident that the COVID-19 pandemic will have an impact on health care costs. We have used available information and reasonable estimation techniques to develop health care cost estimates for the GHIP that reflect the impact of COVID-19. However due to the high degree of uncertainty associated with this pandemic, results may vary from the estimates provided.

² EGWP revenue reflects actual revenues received through June 2023; remaining revenues through CY23 and CY24 based on projected PMPM payments provided by CVS

³ FY24 rebates based on when rebates will be received by GHIP; assumes 60 day lag on CVS rebate payments

Reflects CY22 federal reinsurance true-up payment expected to be received in January 2024
 Participating Group Fees shown for FY24 are estimated based on FY24 fees and assumed FY23 headcounts and premiums
 FY24 projected claims reflect CVS market check contract improvements

Balance Forward reflects actual balance as of June 2023 Fund Equity Report